Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Gains from Investment Securities (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 3 years of Gains from Investment Securities data on record, last reported at -$3.5 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 1056.4% year-over-year to -$3.5 million; the TTM value through Dec 2025 reached -$427000.0, down 247.15%, while the annual FY2025 figure was -$652000.0, N/A changed from the prior year.
  • Gains from Investment Securities reached -$3.5 million in Q4 2025 per ARQT's latest filing, down from $3.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.2 million in Q3 2025 and bottomed at -$3.5 million in Q4 2025.